Assays, Biochemistry, Communication Skills, Cross-Functional, Data Quality, Genomics, High Throughput, Immunology, Molecular Biology, Organizational Skills, Pathology, Pharmacology, Presentation/Verbal Skills, Small Molecules, Team Player, Technical Support, Toxicology, Writing Skills
Design and execute hypothesis-driven mechanistic in vitro and in vivo studies to investigate toxicity findings. Develop and implement cell-based and biochemical assays to assess receptor binding signaling endocytosis and trafficking to support novel ligand candidate derisking and selection.
Assess and implement new technologies to support improve compound toxicity prediction & screening. Preference toward high-throughput or genomics platforms.
Collaborate closely with discovery scientists, toxicologists, and pathologists to deconvolute toxicology issues and ensure strategic investigative alignment for candidate selection.
Communicate study rationale, results, and recommendations through high-quality reports, presentations, and cross-functional meetings.
Maintain high standards of scientific rigor and data integrity.
Requirements:
- Ph.D. degree in Molecular Toxicology, Pharmacology, Immunology, or related field
- 1-3 years relevant experience in academia or industry is preferred
- Demonstrated knowledge in designing and conducting in vitro or in vivo mechanistic studies
- Expertise in characterizing receptor-ligand interactions and downstream cell signaling or cellular function readouts is highly desired
- Technical proficiency in standard cellular and molecular biology techniques
- Experience with high-content imaging and/or flow cytometry is desired
Preferred Qualifications:
- Experience with in vitro and in vivo translational models for safety assessment
- Experience with modalities such as small molecules and biologics
Personal Qualities:
- Highly motivated and organized individual
- Team-oriented mentality
- Enjoy working in fast-paced and collaborative environment
- Excellent written and oral communication skills
A
Alnylam Pharmaceuticals Inc
Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.